Capricor Therapeutics Faces Shareholder Class Action Over Clinical Data

The litigation centers on claims that Capricor misled the market by altering the statistical analysis plan for its drug, Deramiocel, without prior FDA authorization. According to the complaint, the company proceeded with a Biologics License Application resubmission despite failing to secure the necessary regulatory consensus on its methodology. Plaintiffs allege this omission created an undisclosed risk that the FDA would reject the application due to insufficient evidence of the drug's effectiveness.

When these discrepancies surfaced, the resulting market reaction caused significant losses for shareholders. The firm is now inviting those affected to discuss potential recovery options, noting that participation does not require an immediate appointment as lead plaintiff. While the class has not yet been certified, individuals who suffered financial losses during the specified window retain the right to participate in the litigation or remain absent class members. Interested parties may contact Brian Schall or David Schwartz in Los Angeles to review their legal standing.